Haystack Oncology is developing an ultrasensitive, personalized ctDNA-based minimal residual disease (MRD) diagnostic that can detect as few as one mutant molecule in a million DNA molecules. Its Haystack Duo™ platform uses low-error next-generation chemistry and a tumor-informed liquid-biopsy workflow beginning with tissue-based whole-exome sequencing to identify patient-specific tumor mutations and create personalized MRD tests. The company was co-founded in 2021 by Drs. Bert Vogelstein, Ken Kinzler and Nick Papadopoulos, and Joshua Cohen, alongside CEO Dan Edelstein and CTO Dr. Frank Holtrup. Haystack is based in Baltimore, Maryland, with research facilities in Hamburg, Germany. In November 2022 it raised $56M in a Series A led by Catalio Capital Management with participation from Bruker, Exact Ventures and Alexandria Venture Investments to fund continued development and a planned 2023 commercialization of its test. As part of the round, Isaac Ro joined the board as Executive Chairman and Dr. Diamantis Xylas joined as a board observer; Catalio founders George Petrocheilos and Dr. Jacob Vogelstein also serve on the board.

Total raised

$56M

Funding rounds

1

Latest round

Series A

Latest activity

Nov 2022